IDO1 and neoplasm: IDO activity could represent one of the biomarkers of resistance to immunotherapy as universal and agnostic, not linked to individual neoplasms, easily assessable, and virtually useful in treatment planning and in the correct selection of cancer patients for immunotherapy.